Theorem Clinical Research

AstraZeneca

Medimmune, UC San Francisco collaborate

Friday, February 14, 2014 01:40 PM

MedImmune, the global biologics R&D arm of AstraZeneca, has entered a three-year collaboration with the Clinical and Translational Science Institute (CTSI) at the University of California, San Francisco (UCSF).  The collaboration will focus on CTSI's Catalyst Awards program, which solicits applications from University scientists who wish to move their translational research beyond the bench and into product development.

More... »


ACRES, HealthCarePoint strengthen partnership

Wednesday, February 5, 2014 01:18 PM

HealthCarePoint (HCP), a Texas-based healthcare and clinical research networking-technology company, and the Alliance for Clinical Research Excellence and Safety (ACRES), a Cambridge-based nonprofit organization dedicated to enhancing quality, safety, integrity and operational effectiveness in drug development and health research, have announced a second step in their previously announced strategic alliance.

More... »


Bristol-Myers Squibb completes sale of global diabetes business to AstraZeneca

Monday, February 3, 2014 08:51 AM

Bristol-Myers Squibb has completed the previously announced sale of its global diabetes business to AstraZeneca.

More... »

Astrazeneca to close India R&D site

Friday, January 31, 2014 12:49 PM

AstraZeneca plans to close its Avishkar R&D site in Bangalore later this year, part of the company's broader global business strategy to simplify its R&D footprint and focus resources on three core therapy areas: oncology; cardiovascular and metabolic diseases; and respiratory, inflammation and autoimmunity.

More... »

FOB Synthesis, AstraZeneca collaborate on antibiotic-resistant bacterial infections

Wednesday, January 29, 2014 01:02 PM

FOB Synthesis, a chemistry-driven drug discovery and custom synthesis company, has entered into an R&D option and license agreement with AstraZeneca for the development of a novel antibiotic to treat drug-resistant bacterial infections. The treatment will potentially combine compounds from AstraZeneca's preclinical beta lactamase inhibitor (BLI) and FOB Synthesis' preclinical Carbapenem antibiotic programs to help break down bacteria's resistance to carbapenems.

More... »

PTC Therapeutics expands management team

Monday, January 27, 2014 02:47 PM

PTC Therapeutics has expanded its senior management team with the appointment of Robert J. Spiegel, M.D., FACP, to chief medical officer and Murad Husain to vice president, Global Regulatory Affairs. PTC also announced the promotions of Joseph Colacino, Ph.D., to senior vice president, Drug Discovery and Ernest R. Dietel to senior vice president, Quality. In addition, Jay Barth, M.D., senior vice president of Clinical Development, is leaving PTC to pursue other opportunities.

More... »

Former U.K. AstraZeneca R&D site to become science, technology park

Monday, January 20, 2014 11:56 AM

Loughborough, U.K., will be the location for a world-class science and technology park as development of a former AstraZeneca R&D site gets underway. Jayplas acquired the site in 2012 and has confirmed its plans to develop the site into a science park to be known as The Charnwood Biomedical Campus.

More... »

Transcelerate Biopharma recognizes CCRC, CPI certification for good clinical practice

Wednesday, January 15, 2014 11:19 AM

The Association of Clinical Research Professionals (ACRP) has learned that TransCelerate Biopharma now recognizes certification through the Certified Clinical Research Coordinator (CCRC) and Certified Physician Investigator (CPI) programs of ACRP's affiliate, the Academy of Clinical Research Professionals, as evidence of Good Clinical Practice (GCP) training.

More... »

Horizon Discovery, AstraZeneca ink agreement

Wednesday, January 8, 2014 01:26 PM

Horizon Discovery, a provider of research tools to support translational genomics research and the development of personalized medicines, and AstraZeneca have entered into a research, collaboration and license agreement to explore oncology-relevant genotypes with the aim of identifying and validating a number of novel drug targets.

More... »

MedImmune, Immunocore enter immunotherapy agreement

Wednesday, January 8, 2014 01:21 PM

MedImmune, AstraZeneca’s global biologics R&D arm, has entered into an oncology research collaboration and licensing agreement with Immunocore, a privately-held, U.K.-based biotechnology company. Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilizing Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 15

WIRB-Copernicus Group acquires New England IRB

BBK Worldwide secures $3 million in private ἀnancingto accelerate its global and technological expansion

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs